TransCode Therapeutics, Inc. announced significantly improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138. In this study, mice implanted with human GBM tumors treated with TTX-MC138 survival significantly longer than those in the control group. GBM is the most common and aggressive primary brain tumor in adults and has the highest mortality rate among all brain malignancies.

This work will be presented at the 3d Annual Henry Ford + MSU Cancer Research Symposium, "Advancing Cancer Research Through Innovation and Collaboration," November 9-10, 2023, East Lansing, MI. TransCode is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers. In this clinical trial, up to 12 patients will be given a single microdose of radiolabeled TTX-MC138 followed by noninvasive PET-MRI.

The trial is intended to quantify the amount of TTX-MC138 delivered to metastatic lesions and the pharmacokinetics of the therapeutic candidate in cancer patients. The trial could yield important data regarding TTX-MC138 delivery to clinical metastases that could inform dose selection, dosing frequency, and patient selection in later stage clinical trials. This trial is not intended to have therapeutic efficacy.

TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.